secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cytek Biosciences, Inc. (CTKB)
CIK:        0001831915
Form:       8-K
Filed at:   2026-08-05T20:22:06+00:00
Accession:  0001193125-26-335212
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cytek Biosciences Q2 2026 revenue $48.1M (+6% YoY); net loss widens to $12.2M from $5.6M
--------------------------------------------------------------------------------

- Total revenue $48.1M, up 6% YoY; GAAP gross margin improved to 59% from 52%.
- Net loss $12.2M vs $5.6M loss YoY; adjusted EBITDA loss $1.5M vs positive $1.3M.
- Operating expenses rose 15% to $39.7M, driven by litigation, severance, and personnel costs.
- Full-year 2026 revenue guidance raised to $207M-$212M, midpoint up $1M.
- Launched Cytek Borealis 7-laser, 60-color cytometer; installed base reached 3,933 units.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831915/000119312526335212/0001193125-26-335212-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831915/000119312526335212/d118986d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-335212

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer